Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked for GlaxoSmithKline and Zentiva Group across the Central and Eastern Europe (CEE) and the Commonweath of Independent States (CIS) regions and has over 17 years’ experience in the pharmaceutical sector and FMCG.
As CEO, he will be responsible for implementing Saneca’s business growth strategy, driving operational efficiency and ensuring effective project delivery across the business.
Richard Král said: “I am delighted to be appointed as CEO of Saneca. Over the last three years I have developed a comprehensive understanding of the company and I am looking forward to continuing to drive its success and establishing Saneca as the go-to CDMO in Europe.”
“I have a lot of experience in the CEE market, where Saneca is based, and the CDMO’s technical agility and ability to cater for the entire drug life cycle really set it apart from its competitors. We intend to continue our strong growth as we progress through 2018 and it will be extremely rewarding to see the company continue to expand in my new position as CEO.”
Based in western Slovakia, in close proximity to Vienna, Saneca Pharma offers its customers strong capabilities in solids, semi-solids and liquids, as well as specialist expertise in the development and manufacture of opiate active pharmaceutical ingredients (APIs) and finished dosage forms from farm to pharmacy.
For further information please visit